Taking stock of the drug industry, from the lab to the medicine chestJune 20, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer JOEL SAGET/AFP via Getty Images STAT+ | Novo Nordisk sues spas and clinics for selling versions of Wegovy and Ozempic for weight loss Novo Nordisk accused the spas and clinics of false advertising, unfair competition and infringing on trademarks for Ozempic and Wegovy. By Ed Silverman STAT+ | Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal DICE's lead program is an oral drug that aims to inhibit a signaling chemical involved in a cascade of reactions that leads to inflammation. By Matthew Herper STAT+ | 'It's beyond unethical': Opaque conflicts of interest permeate prescription drug benefits A largely hidden flow of money between major consulting firms and PBMs compromises the firms' ability to choose drug benefits for employers. By Bob Herman Maja Hitij/Getty Images STAT+ | How drug pricing reforms are affecting Bayer's investments Despite Democrats' drug pricing reforms, one major pharmaceutical company is doubling down in the U.S. market. By Rachel Cohrs STAT+ | Exact Sciences touts accuracy of updated Cologuard cancer test, but experts want more data While the biotech plans to use the data to apply for regulatory approval, cancer specialists say they need to see more details. By Jonathan Wosen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments